French Trial Tragedy: Dosing Continued After Volunteer Hospitalized
This article was originally published in SRA
Executive Summary
Data from the ill-fated Phase I dose-escalation study of Bial's FAAH inhibitor BIA 10-2474 reveal that the first serious adverse reaction occurred on the fifth day after the daily dose had been increased from 20 mg to 50 mg in the multiple-dosing stage of the trial1,2.
You may also be interested in...
2019 Sees Decline In EMA Drug Approval Recommendations
UK Set For January Brexit After Conservatives Win Election
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
EU Ministers Want Decisive Action On Medicines Access & Shortages
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: